📉 The Financial Deep Dive
Poly Medicure Limited's Q3 FY26 results reveal a stark profit contraction, with consolidated Profit After Tax (PAT) plummeting 75.5% YoY to ₹78.38 Crores from ₹319.29 Crores in Q3 FY25. This sharp decline overshadowed a near-flat revenue performance, which saw a marginal 0.49% YoY decrease to ₹112.82 Crores from ₹113.39 Crores in the prior year.
Sequentially, the picture is equally concerning. Revenue dropped a significant 73.0% QoQ to ₹112.82 Crores from ₹416.54 Crores in Q2 FY26, while PAT saw an 11.9% decline QoQ to ₹78.38 Crores.
For the nine-month period ending December 31, 2025, consolidated PAT fell 58.3% YoY to ₹217.08 Crores from ₹520.40 Crores. Revenue for the nine months grew a modest 1.64% YoY to ₹1,044.17 Crores.
The Quality & The Grill
Profitability was hit by an exceptional item of ₹6.80 Crores, recognised as a provision towards past service cost for gratuity and compensated absences due to new Labour Codes. While the text does not detail specific management guidance or analyst estimates, the substantial drop in profitability warrants close scrutiny of operational efficiency and the true underlying performance.
Financial Deep Dive
The company is undertaking significant inorganic growth initiatives. It is provisionally accounting for the acquisition of the Pendracare group and Medistream SA. The Medistream SA acquisition involved a net cash outflow of approximately ₹235.72 Crores and resulted in the recognition of goodwill, suggesting a premium paid over net assets. Separately, the resolution plan for Himalayan Mineral Water Private Limited has been approved by NCLT, with the company depositing the requisite amount, although acquisition formalities are pending.
Proceeds from a Qualified Institutional Placement (QIP) of approximately ₹1,000 Crores raised earlier are being deployed for share issue expenses, capital expenditure, inorganic initiatives, and general corporate purposes. A significant portion of these funds is temporarily invested in liquid instruments.
Risks & Outlook
The primary risks for Poly Medicure lie in the integration of its recent acquisitions and the ability to translate them into profitable growth. The sharp decline in Q3 PAT, coupled with an exceptional charge, raises questions about margin sustainability and operational leverage. Investors will need to monitor how the company manages the goodwill recognised from the Medistream acquisition and the overall financial leverage post these deals. The near-term outlook depends heavily on the performance of these new ventures and the broader market demand for its products, which has shown some sequential weakness.